To test this, 89Zr-labelled anti-HER2 antibody trastuzumab and its non-specific 111In-labelled counterpart were co-administered to mice bearing one of four human breast cancer xenografts with varying HER2 expression levels. This evidence concerns the gene ERBB2 and breast cancer.